3,396 results match your criteria Polymyalgia Rheumatica

Catastrophic, Bilateral Retinal Vascular Occlusion after Intravitreal Bevacizumab Injection.

Retin Cases Brief Rep 2021 May 10. Epub 2021 May 10.

West Coast Retina Medical Group, San Francisco, California. The Department of Ophthalmology, California Pacific Medical Center, San Francisco, California. Massachusetts Eye and Ear Infirmary, Harvard Medical School, Ocular Immunology and Uveitis Service, Boston, Massachusetts. The Department of Ophthalmology, Stanford University School of Medicine, Stanford, California. The Francis I. Proctor Foundation, UCSF School of Medicine, San Francisco, California. Massachusetts Eye and Ear Infirmary, Harvard Medical School, Vitreoretinal Service, Boston, Massachusetts. Ophthalmic Consultants of Boston, Vitreoretinal Service, Boston, Massachusetts. Ophthalmic Consultants of Boston, Uveitis Service, Boston, Massachusetts.

Purpose: To describe two cases of catastrophic, bilateral retinal vascular occlusion following intravitreal (IVT) bevacizumab injection.

Methods: Case series. Main outcome measures included clinical and fluorescein angiography (FA) findings. Read More

View Article and Full-Text PDF

Reliability of activity monitors for physical activity assessment in patients with musculoskeletal disorders: A systematic review.

J Back Musculoskelet Rehabil 2021 Apr 27. Epub 2021 Apr 27.

IRCCS Istituto Ortopedico Galeazzi, Milan, Italy.

Background: Activity monitors have been introduced in the last years to objectively measure physical activity to help physicians in the management of musculoskeletal patients.

Objective: This systematic review aimed at describing the assessment of physical activity by commercially available portable activity monitors in patients with musculoskeletal disorders.

Methods: PubMed, Embase, PEDro, Web of Science, Scopus and CENTRAL databases were systematically searched from inception to June 11th, 2020. Read More

View Article and Full-Text PDF

Antimitochondrial Antibodies and Primary Biliary Cholangitis in Patients with Polymyalgia Rheumatica/Giant Cell Arteritis.

Medicina (Kaunas) 2021 Apr 6;57(4). Epub 2021 Apr 6.

Azienda Ospedaliera "Pugliese-Ciaccio", Geriatric Medicine Department, 88100 Catanzaro, Italy.

: Laboratory liver abnormalities can be observed in patients affected with polymyalgia rheumatica (PMR) and/or giant cell arteritis (GCA), especially with a cholestatic pattern. The first objective of our review article is to discuss the potential link between antimitochondrial antibodies (AMA) and/or primary biliary cholangitis (PBC) and PMR/GCA, according to the evidences of literature. The second objective is to discuss the association of PMR/GCA with the other rheumatic diseases having PBC as a common manifestation. Read More

View Article and Full-Text PDF

Nivolumab-induced polymyalgia rheumatica in a patient with lung adenocarcinoma.

Am J Med Sci 2021 Apr 24. Epub 2021 Apr 24.

Department of Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan.

A 79-year-old woman was diagnosed with stage IV (cT1aN1M1, OSS) lung adenocarcinoma with bone metastasis of the right femur. She received nivolumab as a third-line treatment. She developed pain in the right shoulder, left wrist, right knee, and waist as well as a low-grade fever and morning stiffness, after five courses of nivolumab. Read More

View Article and Full-Text PDF

[Rheumatic immune adverse events related to immune checkpoint inhibitors-(IrAEs related to ICI)].

Bull Cancer 2021 Apr 23. Epub 2021 Apr 23.

Centre hospitalier Lyon Sud-hospices civils de Lyon, service de rhumatologie, centre expert des métastases et d'oncologie osseuse secondaire (CEMOS), 69310 Pierre Bénite, France; Université de Lyon, Inserm UMR 1033-LYOS, 69003 Lyon, France; Institut de cancérologie des hospices Civils de Lyon, ImmuCare (Immunology cancer research), 69310 Pierre Bénite, France. Electronic address:

New anti-cancer therapeutics have been developed in the recent years and dramatically change prognosis and patient management. Either used alone or in combination, immune checkpoint inhibitors (ICI), such as anti-CTLA-4 and anti-PD1/PD-(L)1, act by removing T-cell inhibition to enhance their antitumor response. This change in therapeutic targets leads to a break in immune-tolerance and a unique toxicity profile resulting in immune complications. Read More

View Article and Full-Text PDF

Endorsement of the OMERACT core domain set for shared decision making interventions in rheumatology trials: Results from a multi-stepped consensus-building approach.

Semin Arthritis Rheum 2021 Apr 6. Epub 2021 Apr 6.

Institute for Work & Health, Institute Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada.

Objective: To gain consensus on the Outcome Measures in Rheumatology (OMERACT) core domain set for rheumatology trials of shared decision making (SDM) interventions.

Methods: The process followed the OMERACT Filter 2.1 methodology, and used consensus-building methods, with patients involved since the inception. Read More

View Article and Full-Text PDF

The validity of the claims-based definition of rheumatoid arthritis evaluated in 64 hospitals in Japan.

BMC Musculoskelet Disord 2021 Apr 22;22(1):373. Epub 2021 Apr 22.

Rheumatology Center, Chiba-Nishi General Hospital, Matsudo, Chiba, Japan.

Background: An administrative database covering a whole population such as the national database in Japan may be used to estimate the nationwide prevalence of diseases including rheumatoid arthritis (RA) when a well-validated definition of the disease is available. In Japan, the record linkage between the administrative database and medical charts in hospitals is strictly prohibited. A "hospital-based" validation study is one of few possible validation studies where claims kept inside the study hospital are rearranged into the database structure. Read More

View Article and Full-Text PDF

Fast track clinic for early diagnosis of polymyalgia rheumatica: Impact on symptom duration and prednisolone initiation.

Joint Bone Spine 2021 Apr 19;88(5):105185. Epub 2021 Apr 19.

Department of Rheumatology, Diagnostic Centre, Silkeborg Regional Hospital, Falkevej 1, 8600 Silkeborg, Denmark. Electronic address:

Objectives: To evaluate the efficacy of a fast track clinic (FTC) for patients suspected of polymyalgia rheumatica (PMR) regarding symptom duration, prednisolone initiation before rheumatological assessment, number of hospital contacts before diagnosis, and cancer diagnosis.

Methods: It is a retrospective cohort study with a one year follow-up period. Patients referred to the FTC (1st August 2016 to 25th June 2019) were compared to a historical cohort of PMR patients (1st August 2014 to 1st August 2016). Read More

View Article and Full-Text PDF

A fatal case of COVID-19-associated invasive pulmonary aspergillosis.

J Infect Chemother 2021 Apr 1. Epub 2021 Apr 1.

Department of Respiratory Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.

A 79-year-old Japanese man with polymyalgia rheumatica was admitted to hospital with coronavirus disease (COVID-19). On admission, he was treated with ciclesonide inhalation, ivermectin, and meropenem. He was intubated 6 days after admission, and methylprednisolone therapy was initiated (1000 mg/day). Read More

View Article and Full-Text PDF

Does methotrexate have no beneficial effect in reducing flares in the treatment of polymyalgia rheumatica patients?

Rheumatol Int 2021 Apr 15. Epub 2021 Apr 15.

Systematic Review Workshop Peer Support Group (SRWS-PSG), Osaka, Japan.

We read the article by Marsman et al. regarding the efficacy of methotrexate (MTX) in the treatment of polymyalgia rheumatica (PMR) with great interest. This study added new insights regarding the use of MTX in a real-world clinical setting and its effect on the incidence rates of flares. Read More

View Article and Full-Text PDF

F-fluorodeoxyglucose positron emission tomography/computed tomography of giant cell arteritis with lower extremity involvement in association with polymyalgia rheumatica.

World J Nucl Med 2021 Jan-Mar;20(1):90-92. Epub 2020 Oct 2.

Department of Radiology, Mayo Clinic, Rochester, MN, USA.

An 80-year-old man presented with new-onset pain in the shoulders and lower extremities and elevated serum inflammatory markers. A clinical diagnosis of polymyalgia rheumatica (PMR) was made, but there was a suboptimal response to glucocorticoid therapy, prompting further evaluation. F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) revealed intense FDG uptake in the arteries of the bilateral lower extremities, head, and neck, but sparing the aorta, suggestive of an uncommon pattern of giant cell arteritis (GCA). Read More

View Article and Full-Text PDF
October 2020

[An update on giant cell arteritis].

Rev Med Chil 2020 Nov;148(11):1619-1629

Departamento de Radiología, Clínica Las Condes, Santiago, Chile.

Giant cell arteritis (GCA) is a primary granulomatous systemic vasculitis involving the aorta and its main branches that affects people aged over 50 years with a genetic predisposition. Its main phenotypes are cranial and extracranial involvement, with or without symptoms of polymyalgia rheumatica. These phenotypes can overlap. Read More

View Article and Full-Text PDF
November 2020

Clinical and FDG-PET/CT correlates in patients with polymyalgia rheumatica.

Clin Exp Rheumatol 2021 Mar 30. Epub 2021 Mar 30.

Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Italy.

Objectives: We aimed to evaluate joint and vessel uptake in patients with polymyalgia rheumatica (PMR) by FDG-PET and correlate it with clinical findings.

Methods: Consecutive PMR patients, without clinical signs of giant cell arteritis, underwent a standardised clinical examination and FDG-PET/CT. Controls were consecutive subjects undergoing FDG-PET for the suspicion of neoplasm not confirmed by the examination. Read More

View Article and Full-Text PDF

Seasonal onset of polymyalgia rheumatica: correlations with the pattern of clinical presentation, disease severity and outcome in 383 patients from a single centre.

Clin Exp Rheumatol 2021 Mar 30. Epub 2021 Mar 30.

Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Italy.

Objectives: Polymyalgia rheumatica (PMR) is an inflammatory disorder, more common in the elderly, characterised by girdle pain and stiffness, constitutional symptoms and raised serological markers of inflammation. Studies on the seasonality of onset of PMR have shown conflicting results, possibly due to the different diagnostic criteria and onset recognition. In this study, the month of onset of PMR was evaluated in patients originating from one geographical area, visited by the same clinician. Read More

View Article and Full-Text PDF

Sternoclavicular Joint Hypertrophy Involved in Polymyalgia Rheumatica.

Intern Med 2021 Apr 5. Epub 2021 Apr 5.

Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan.

View Article and Full-Text PDF

Tocilizumab vs placebo for the treatment of giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms or both in a randomized trial.

Semin Arthritis Rheum 2021 Apr 18;51(2):469-476. Epub 2021 Mar 18.

Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Objective: The randomized, placebo (PBO)-controlled GiACTA trial demonstrated the efficacy and safety of tocilizumab (TCZ) in patients with giant cell arteritis (GCA). The present study evaluated the efficacy of TCZ in patients with GCA presenting with polymyalgia rheumatica (PMR) symptoms only, cranial symptoms only or both PMR and cranial symptoms in the GiACTA trial.

Methods: In GiACTA, 250 patients with GCA received either TCZ weekly or every other week plus a 26-week prednisone taper or PBO plus a 26- or 52-week prednisone taper. Read More

View Article and Full-Text PDF

Giant Cell Arteritis among Fevers of Unknown Origin (FUO): An Atypical Presentation.

Eur J Case Rep Intern Med 2021 9;8(3):002254. Epub 2021 Feb 9.

Department of Internal Medicine, Ospedale Regionale di Lugano, Ente Ospedaliero Cantonale, Lugano, Switzerland.

Giant cell arteritis (GCA), or Horton's arteritis, presenting solely as fever is very rare. Usually, it manifests with typical features such as visual problems, headache and jaw claudication, or it can be associated with polymyalgia rheumatica. We describe the case of a patient with GCA who presented only with prolonged fever, the cause of which was not determined by diagnostic tests. Read More

View Article and Full-Text PDF
February 2021

Rheumatologic diseases impact the risk of progression of MGUS to overt multiple myeloma.

Blood Adv 2021 Mar;5(6):1746-1754

Department of Internal Medicine V, Haematology and Medical Oncology, and.

Monoclonal gammopathy of undetermined significance (MGUS), a premalignant condition, is associated with various chronic inflammatory rheumatic diseases (RDs) and is frequently observed as an incidental finding during routine work-up. The association of MGUS and chronic RDs is well established, but the impact of RDs on the risk of transformation into overt multiple myeloma (MM) has not been evaluated so far. MGUS patients diagnosed between January 2000 and August 2016 were identified and screened for concomitant RDs. Read More

View Article and Full-Text PDF

Inflammatory Markers are Quickly Improved by Tocilizumab in Early Polymyalgia Rheumatica and Might Predict Early Response to Interleukin-6 Blockade.

Rheumatol Ther 2021 Mar 21. Epub 2021 Mar 21.

Rheumatology Department, CHRU Cavale Blanche, Brest, France.

Introduction: It is unclear whether polymyalgia rheumatica (PMR) should be considered an inflammatory disease or an autoimmune disease.

Methods: Eighteen untreated early PMR patients and 18 sex- and age-matched healthy controls (HCs) were included. PMR patients received tocilizumab from week 0 to week 12 and glucocorticoids from week 12 to week 24. Read More

View Article and Full-Text PDF

Prognostic impacts of glucocorticoid treatment in patients with polymyalgia rheumatica and giant cell arteritis.

Sci Rep 2021 Mar 18;11(1):6220. Epub 2021 Mar 18.

Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.

Identifying comorbidities in polymyalgia rheumatica/giant cell arteritis (PMR/GCA) is crucial for patients' outcomes. The present study aimed to evaluate the impact of the inflammatory process and glucocorticoid treatment on aortic arterial stiffness and body composition in PMR/GCA. 77 patients with newly diagnosed PMR/GCA were treated with oral glucocorticoids and followed for 40 weeks. Read More

View Article and Full-Text PDF

Images in Vascular Medicine: Usefulness of carotid ultrasonography for diagnosis and management of polymyalgia rheumatica-associated large-vessel vasculitis.

Vasc Med 2021 Mar 18:1358863X21995582. Epub 2021 Mar 18.

Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Ube City, Yamaguchi Prefecture, Japan.

View Article and Full-Text PDF

The Immunopathology of Giant Cell Arteritis Across Disease Spectra.

Front Immunol 2021 25;12:623716. Epub 2021 Feb 25.

Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States.

Giant cell arteritis (GCA) is a granulomatous systemic vasculitis of large- and medium-sized arteries that affects the elderly. In recent years, advances in diagnostic imaging have revealed a greater degree of large vessel involvement than previously recognized, distinguishing classical cranial- from large vessel (LV)- GCA. GCA often co-occurs with the poorly understood inflammatory arthritis/bursitis condition polymyalgia rheumatica (PMR) and has overlapping features with other non-infectious granulomatous vasculitides that affect the aorta, namely Takayasu Arteritis (TAK) and the more recently described clinically isolated aortitis (CIA). Read More

View Article and Full-Text PDF
February 2021

Back to the future: identification and classification of polymyalgia rheumatica and polymyalgia rheumatica-like syndromes following cancer immunotherapy with checkpoint inhibitors.

Reumatologia 2021 28;59(1):62-63. Epub 2021 Feb 28.

Library and Knowledge Services, Central and North West London NHS Foundation Trust, London, United Kingdom.

Polymyalgia rheumatica (PMR) and PMR-like syndromes are among the most frequent rheumatologic immuno-related adverse events (IRAEs) induced by cancer immunotherapy with "checkpoint inhibitors" (ICIs). Our short communication addresses two key methodological issues laid bare by published literature : 1) how to diagnose PMR and PMR-like syndromes following ICI therapy, 2) how PMR/PMR-like syndromes following ICI therapy are described as adverse drug reactions (ADRs). Read More

View Article and Full-Text PDF
February 2021

Decision Tree With Only Two Musculoskeletal Sites to Diagnose Polymyalgia Rheumatica Using [F]FDG PET-CT.

Front Med (Lausanne) 2021 17;8:646974. Epub 2021 Feb 17.

Department of Nuclear Medicine, Jean Perrin Oncology Institute of Clermont-Ferrand, Clermont-Ferrand, France.

The aim of this study was to find the best ordered combination of two FDG positive musculoskeletal sites with a machine learning algorithm to diagnose polymyalgia rheumatica (PMR) vs. other rheumatisms in a cohort of patients with inflammatory rheumatisms. This retrospective study included 140 patients who underwent [F]FDG PET-CT and whose final diagnosis was inflammatory rheumatism. Read More

View Article and Full-Text PDF
February 2021

Diagnosis and Treatment of Polymyalgia Rheumatica.

Radiol Technol 2021 Mar;92(4):383-398

Has 28 years of experience in the nuclear medicine field and recently retired as the program director for the nuclear medicine and PET-CT programs at Thomas Jefferson University in Philadelphia, Pennsylvania. She formerly served on the Radiologic Technology Editorial Review Board, ASRT Practice Standards Council, and ASRT Foundation Scholarship Review Committee. She is a former recipient of the International Speakers Exchange Award.

Polymyalgia rheumatica (PMR) is an inflammatory condition that occurs in older adults. Its cause is unclear but might be autoimmune, autoinflammatory, environmental, or genetic. Patients with PMR have proximal joint pain and stiffness that limit mobility and decrease quality of life. Read More

View Article and Full-Text PDF

Drugs Recommended in Adult Rheumatic Diseases, But Considered for Off-Label Use in Argentina.

Reumatol Clin 2021 Feb 24. Epub 2021 Feb 24.

Servicio de Reumatología, Hospital J. M. Ramos Mejia, Urquiza 609, Ciudad Autónoma de Buenos Aires, Argentina.

Background: Off-label (OL) drug use is the prescription of a drug for indications other than those authorised in its technical datasheet. The objective of this study was to identify drugs recommended in rheumatology but considered for off-label use in Argentina.

Methods: A list of medications for certain selected rheumatic conditions was compiled. Read More

View Article and Full-Text PDF
February 2021

Treatment Patterns, Disease Burden, and Outcomes in Patients with Giant Cell Arteritis and Polymyalgia Rheumatica: A Real-World, Electronic Health Record-Based Study of Patients in Clinical Practice.

Rheumatol Ther 2021 Mar 26;8(1):529-539. Epub 2021 Feb 26.

Genentech, Inc., South San Francisco, CA, USA.

Introduction: Because of the chronic nature of giant cell arteritis (GCA) and/or polymyalgia rheumatica (PMR), patients may require continued glucocorticoid treatment to achieve treatment targets or prevent disease relapse, resulting in high cumulative doses. This study evaluated patterns of glucocorticoid use and outcomes in patients with GCA, PMR, or both.

Methods: This retrospective study used electronic medical records from a US rheumatology clinic utilizing the JointMan (Discus Analytics, LLC) rheumatology software. Read More

View Article and Full-Text PDF

Reply to: Calcium pyrophosphate disease and polymyalgia rheumatica: association or coincidence?

Clin Exp Rheumatol 2021 Feb 9. Epub 2021 Feb 9.

Université Paris Diderot, Sorbonne Paris Cité, UFR de Médecine, F-75025 Paris, France; AP-HP, Service de Rhumatologie, Hôpital Bichat, Paris, France.

View Article and Full-Text PDF
February 2021

Seasonal influence on incidence of polymyalgia rheumatica: winter might be coming.

Clin Exp Rheumatol 2021 Jan-Feb;39 Suppl 128(1):19-20. Epub 2021 Feb 19.

Department of Rheumatology, Sint Maartenskliniek, Nijmegen, The Netherlands.

View Article and Full-Text PDF
February 2021